Temocilina para infecciones del tracto no urinario causadas por Enterobacterales productores de AmpC: ¿Es una opción...

Infections due to AmpC-producing Enterobacterales represent an increasing therapeutic challenge. Third-generation cephalosporins may select resistant mutants, inducing clinicians to use cefepime or carbapenems and thereby contributing to carbapenem resistance. While temocillin is a narrow-spectrum beta-lactam stable against AmpC enzymes, evidence of its impact in non-urinary tract infections remains limited.

We conducted a retrospective study of adult patients treated with temocillin for non-urinary tract infections caused by AmpC-producing Enterobacterales between 2016 and 2021. Clinical, microbiological and therapeutic data were collected. The primary outcome was treatment failure within twenty-eight days.

Six patients were included, with a median age of sixty-one years; three required intensive care. Infection sites were digestive or respiratory. All patients had achieved clinical cure by day twenty-eight, without recurrence, infection-related mortality, or adverse events.

Having led to favorable outcomes, temocillin may represent a carbapenem-sparing option when in vitro susceptibility is confirmed. These findings call for further evaluation in larger prospective clinical studies.